Biotia

Founded in 2015 and based in New York, Biotia operates at the intersection of genomics, AI, and infectious disease diagnostics. Its core offerings include the clinically validated BIOTIA-ID diagnostic assays for complex infections and urinary tract infections (UTIs), and the GeoSeeq platform, a global pandemic early warning system that integrates data from distributed labs. The company has established significant partnerships with prestigious academic and healthcare institutions and has achieved key regulatory milestones, such as securing a PLA code for its urine assay, positioning it in the commercial stage for diagnostics.

Next-generation sequencing (NGS) combined with proprietary AI/machine learning software for pathogen detection, genomic analysis, and pandemic forecasting.

Biotia competes with large diagnostic companies (e.g., Roche, Abbott, bioMérieux) offering traditional and molecular tests, as well as a growing field of NGS-based infectious disease diagnostic startups (e.g., Karius, Day Zero Diagnostics). In pandemic surveillance, it faces competition from other data/AI-driven health intelligence platforms and government-led initiatives.